Portfolio company Araris Biotech agreed to be acquired by Taiho Pharmaceutical for up to $1.14B, a landmark exit for the firm.
Araris Biotech AG is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology that enables the attachment of payloads to 'off-the-shelf' antibodies in one step, resulting in highly homogenous, stable, and potent ADC therapies for targeted cancer treatment
Araris Biotech AG is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology that enables the attachment of payloads to 'off-the-shelf' antibodies in one step, resulting in highly homogenous, stable, and potent ADC therapies for targeted cancer treatment.